to prevent the reduction of testosterone responses caused by intravenous hCG and subcutaneous GnRH. In addition, Tamoxifen significantly increased the number of LH receptors in Leydig cells from both control and gonadotropin-desensitized animals. These findings indicate that the acute elevations of intratesticular estrogen produced by treatment with hCG or GnRH are responsible for the steroidogenic lesion seen in gonadotropin-desensitized Leydig cells. These results also suggest that locally produced estrogens contribute to the regulation oftesticular LH receptors and 17,20 desmolase activity.
A B S T R A C T Leydig cells isolated from the testes of rats treated with intravenous exogenous gonadotropin (hCG) or subcutaneous gonadotropin-releasing hormone (GnRH) show markedly decreased luteinizing hormone (LH) receptors and a partial block in testicular 17, 20 desmolase activity. In contrast, Leydig cells from animals with equivalent degrees of LH receptor loss induced by subcutaneous hCG treatment show no change in 17,20 desmolase activity. These findings indicated that the acuteness of gonadotrophic stimulation, rather than the extent of LH receptor loss, was responsible for the steroidogenic lesion. A role of estradiol in the enzymatic block produced in vivo by acute elevation of circulating gonadotropin (intravenous hCG or GnRH-stimulated endogenous LH) was suggested by rapid elevations of testicular 17,8- estradiol within 30 min after intravenous hCG, whereas more gradual increases in estradiol occurred 4-8 h after subcutaneous hCG. The inhibitory effect of endogenous estrogen on testicular steroidogenesis was confirmed by the ability of an estrogen antagonist (Tamoxifen) to prevent the reduction of testosterone responses caused by intravenous hCG and subcutaneous GnRH. In addition, Tamoxifen significantly increased the number of LH receptors in Leydig cells from both control and gonadotropin-desensitized animals. These findings indicate that the acute elevations of intratesticular estrogen produced by treatment with hCG or GnRH are responsible for the steroidogenic lesion seen in gonadotropin-desensitized Leydig cells. These results also suggest that locally produced estrogens contribute to the regulation oftesticular LH receptors and 17, 20 (1) . Acute elevations of endogenous LH, by single subcutaneous doses of gonadotropin-releasing hormone (GnRH), caused a similar steroidogenic lesion with accumulation of 17a-hydroxyprogesterone during stimulation of the desensitized Leydig cells in vitro (2, 3) . The occurrence of simultaneous increases in progesterone production suggested the presence of an additional lesion at the level of 17a-hydroxylase. In addition to the negative effects observed after desensitization (i.e., receptor depletion and reduced testosterone responses), there is also increased formation of pregnenolone (1) (2) (3) (4) (1) .
In other experiments, groups of rats were studied after the following treatments (a) control; (b) intravenous injection of 1 ,ug hCG; (c) intravenous injection of 1 ,ug hCG plus 1.5 jig Tamoxifen i.v. and 1.5 ,ug i.m.; (d) subcutaneous injections of 10 ,ug hCG. The rats were killed at selected times after the injections (0.5, 1, 2, 4, and 8 h). Blood samples collected from the decapitated animals were allowed to clot, and serum was stored at -700C before testosterone analysis. Testes were removed and kept frozen at -700C until analyzed for estradiol-17,3, testosterone, progesterone, and 17a-hydroxyprogesterone.
Assays of steroids and serum hCG. Decapsulated testes were homogenized in 2 ml of PBS/testis and extracted with ethyl acetate after addition of tracer amounts of 3H-steroids to account for losses during the fractionation procedure. As previously described (11), testosterone was measured by direct radioimmunoassay in the incubation media diluted 1:10 or 1:25 with PBS. The testosterone content of testis extracts and serum was determined after isolation of the steroid by thin-layer chromatography (12) . Pregnenolone was measured by the method of di Pietro et al. (13) with a highly specific rabbit antiserum to the 11-hemisuccinate albumin conjugate. Radioimmunoassay of 17a-hydroxyprogesterone was performed with an antiserum to the 3-carboxymethyloxime derivative. Because the antiserum to 17a-hydroxyprogesterone showed significant cross-reactivity with progesterone (14%), the two steroids were separated by thin-layer chromatography before assay, when progesterone was present in testis extracts. 17,8-estradiol assays were performed as described by Wung and Lundey (14) using a highly specific rabbit antiserum to 6-ketoestradiol conjugated to bovine serum albumin (Steraloids, Wilton, N. H.). Only minor cross-reaction was observed with the following phenolic steroids: estrone 0.83%; estriol 0.67%; 16-ketoestradiol 1.8%; 16-epiestriol 3.8%; estradiol-3-glucuronide 0.69%; estradiol-17-glucuronide 0.091%. No cross-reaction was observed with any other steroid tested, including testosterone, androstenedione, progesterone, pregnenolone, 17a-hydroxypregnenolone, 17a-hydroxyprogesterone, estradiol 3,17 disulfate, and estradiol-3-glucuronide. All steroids that showed minor cross-reaction were well resolved during the chromatographic separation used in this study. Almost identical values were obtained when extracts were purified by LH-Sephadex (Pharmacia Fine Chemicals Inc., Piscataway, N. J.) column chromatography before assay. Immunoreactive serum hCG concentrations were measured by a specific assay procedure employing anti-hCG,8 as the first antibody (15 (Fig. 2) . In 2 ofthe 10 experiments, significant increases of 30-50% (P < 0.001) in basal and hCG-stimulated testosterone production were observed during incubation of Leydig cells from Tamoxifen-treated control (i.e., nondesensitized) animals, as shown by the experiment illustrated in Fig. 3 . This experiment also demonstrates the marked reduction of hCG-stimulated testosterone production by Leydig cells from intravenous hCG-desensitized animals. Tamoxifen administration with hCG prevented this reduction in maximal testosterone response. In this experiment Tamoxifen again increased the number of LH receptors above the control value (21, 190 vs. 17, 830 LH sites/cell, P < 0.01). Similarly, in hCG-desensitized animals, with reduction of LH receptors to 1,120 sites/cell (6.8% of control), a significant increase in receptor number was produced by treatment with Tamoxifen (to 2,520 sites/cell or 11.8% of the Tamoxifen-treated control group).
The testicular contents oftestosterone, progesterone, and 17a-hydroxyprogesterone in these experiments are shown in Table I . The testosterone content of the testis reached near-maximal values from 30 to 60 min after intravenous hCG injection, similar to the increase observed in plasma testosterone (Fig. 1) , and remained elevated for up to 8 h. In contrast, subcutaneous injection of hCG caused a gradual increase in the testosterone content of the testis, reaching maximal levels at 8 h. This change in testicular testosterone paralleled the rise in serum hCG and the testicular estradiol content, but diverged from the serum testosterone concentration, which decreased between 4 and 8 h. The peak in testicular testosterone content was observed at 30 min, coincident with the peak of serum hCG, and was significantly higher in the tamoxifen- treated group (P < 0.01) at 30 min and 2 h after hCG administration. The progesterone and 17a-hydroxyprogesterone levels were generally lower in the intravenous hCG/tamoxifen-treated group than in the intravenous hCG group, but these differences were not statistically significant. The ratios of testosterone: progesterone and testosterone: 17a-hydroxyprogesterone were significantly higher in the tamoxifen-treated group than in the intravenous hCG group (P < 0.05). Tamoxifen was also found to inhibit the steroidogenic lesion in GnRH-desensitized cells (Fig. 4) , in which the reduction of maximal testosterone responses to hCG was prevented by simultaneous treatment with the antiestrogen.
DISCUSSION
The major implications of these results are that acute changes in testicular estrogens are involved in the regulation of 17,20 desmolase activity in the Leydig cell, and that increased estradiol production is responsible for the impairment of androgen production in gonadotropin-desensitized Leydig cells. The inhibitory effect of endogenous estradiol-17,8 on the activity ofthe 17,20 desmolase and 17a-hydroxylase enzymes, presumably exerted via the estrogen receptors of the Leydig cell (17) , is indicated by the ability of Tamoxifen to prevent the characteristic impairment of maximal testosterone production exhibited by desensitized Leydig cells in vitro.
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S. E. Cigorraga, S. Sorrell, J. Bator, K. J. Catt, and M. L. Dufau high doses of Tamoxifen (18) and the direct effects of Tamoxifen on aromatase activity (19) . Low doses of Tamoxifen have been shown to produce significant antiuterotropic effects, and single subcutaneous doses of 10 ug Tamoxifen depleted cytoplasmic uterine estrogen receptors by 75% at 3-8 h, followed by low receptor levels for 24 h and a return to normal at 48 h (20) . In the present study estrogen increases were observed within the 8 h following acute rises of plasma gonadotropin after intravenous hCG or elevation of endogenous LH by GnRN, at the time when maximal cytoplasmic receptor depletion would presumably occur after Tamoxifen treatment. The estrogen levels returned to control values at 16 h before the return of estradiol receptors after tamoxifen treatment.2 A small but significant increase in LH/hCG receptors was consistently observed in the Tamoxifen-treated animals, both in controls and in gonadotropin-desensitized testes. This finding is relevant to our previous observation that estrogen treatment reduced the concentration of testicular LH receptors in hypophysectomized animals, and prevented the rise of LH receptors induced by follicle-stimulating hormone treatment (21) . Therefore, it appears likely that the intratesticular concentration of estrogen modulates the number of LH receptors in the Leydig cell. How-ever, the retention of Leydig cell responses observed in this study after Tamoxifen treatment was not attributable to the increased number of LH receptors, because previous experiments (1, 3, 4) in desensitized cells showed that retention of up to 35% of the receptors was accompanied by 50-80% impairment of testosterone production.
The prevention of steroidogenic lesions by Tamoxifen is exerted through the antiestrogenic effect of this compound, by inhibiting the partial block of 17, 20 desmolase caused by acute elevation of estrogen after intravenous hCG or elevations of endogenous LH by GnRH treatment. A direct inhibitory effect of estrogen on testosterone production by Leydig cells has been demonstrated in hypophysectomized rats treated with follicle-stimulating hormone. In such animals, treatment with low doses of estrogen abolished the folliclestimulating hormone-induced testicular changes in a dose-dependent manner (i.e., testosterone responses to hCG, LH receptors, and testicular weight [21] ). Also, administration of diethylstilbestrol to men with prostatic cancer resulted in a marked decrease of circulating testosterone levels (to 5% of control) with only moderate reductions in plasma LH (22) . Such findings have indicated the ability of pharmacological amounts of estrogen to exert a direct inhibitory effect on testicular androgen production, and this has been localized in rodents to the 17,20 desmolase step (5). The present observations have shown that physiological changes in estrogen production also influence 17, 20 desmolase activity and androgen production, and suggest that endogenous estrogen may have a tonic inhibitory action in the normal control of testicular steroidogenesis.
In man, the present findings may be relevant to the reduced gonadal testosterone production rates observed in Klinefelter's syndrome (23, 24) . Such patients have low testicular venous and peripheral plasma testosterone levels and high plasma 17a-hydroxyprogestL-rone levels (25) . This steroidogenic pattern suggests the presence ofa lesion ofthe 17, 20 desmolase enzyme, as observed in the gonadotropin-desensitized rat testis. Increased conversion of testosterone to estrogen has been shown to occur in the testis (26) and, peripherally (23) , in Klinefelter's syndrome, and similar changes are found in elderly men and patients with hepatic cirrhosis (27, 28) . Thus, testicular estrogen seems to exert a modulatory effect on the 17,20 desmolase step and upon androgen production by the testis, and this may be increased in conditions associated with elevated estrogen production. Normally testosterone production is probably influenced by a tonic inhibitory effect of estrogen produced in the testis, and that reaching the testis from peripheral sites of aromatization. Although thi § effect may be minor under normal conditions, it becomes more prominent when estrogen production is increased, as in the clinical conditions noted above and in the experimental model of desensitization (1) (2) (3) (4) . In the latter, marked suppression of 17,20 desmolase enzymatic activity is clearly responsible for the accompanying decrease in testosterone production (1, 3, 4) .
Our current views on the mechanism of desensitization in relation to steroidogenesis are summarized as follows. Treatment with hCG or GnRH (via endogenous LH) produces: LH receptor down-regulation; increased steroidogenic capacity and testosterone production, with increased estrogen formation from androgen; subsequently, estrogen causes a decrease in the enzymatic activity of 17, 20 desmolase and probably of 17a-hydroxylase, with reduced androgen production and increases in 17a-hydroxyprogesterone and progesterone. These biosynthetic lesions are prevented when Tamoxifen is administered with the desensitizing dose of gonadotropin. Although direct actions of GnRH in the testis have recently been demonstrated (29) , the acute changes observed after GnRH treatment in the present work are similar to those caused by hCG and are attributable to the effect of endogenous LH elevations upon testicular estrogen production.
The effects of exogenous and endogenous gonadotropins on the testis are complex, because the initial activation process is followed by decreased LH receptors and steroid biosynthetic lesions. In addition to the estrogen-dependent steroidogenic block described in this report, an earlier biosynthetic lesion has been noted in Leydig cells after treatment with high doses of hCG that caused almost complete depletion of testicular LH receptors (1, 4) . The basis of the lesion, which is before pregnenolone biosynthesis, has yet to be determined, but may also depend on hyperstimulation of the Leydig cell rather than the prominent change in LH receptor content. The elucidation of steroid biosynthetic lesions produced during hormonal stimulation should contribute to the definition of the intracellular control mechanisms that regulate the steroidogenic enzymes of the Leydig cell.
